Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qingyi Shi

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Global Antimicrobial Resistance|January 12, 2019
A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infectionsTingting Xiao, Zhenzhu Wu, Qingyi Shi, et al.
Infection and Drug Resistance|June 14, 2019
Simulating moxalactam dosage for extended-spectrum β-lactamase-producing <i>Enterobacteriaceae</i> using blood antimicrobial surveillance network dataChen Huang, Qingyi Shi, Beiwen Zheng, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 19, 2022
Cefepime, not Piperacillin/Tazobactam use, for empirical treatment of bloodstream infections caused by Enterobacter spp.: Results from a population pharmacokinetic/pharmacodynamic analysisQingyi Shi, Chen Huang, Weizhuang Chen, et al.
Infection and Drug Resistance|May 8, 2018
In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant <i>Klebsiella pneumoniae</i>Wei Yu, Qixia Luo, Qingyi Shi, et al.
Clinical and Experimental Rheumatology|April 23, 2026
BLyS/APRIL dual inhibition for systemic sclerosis: a single-centre, single-arm, open-label clinical trial of telitaciceptQingyi Shi, Jin Zhang, Qiuxia Yu, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Global Antimicrobial Resistance|January 12, 2019
A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infectionsTingting Xiao, Zhenzhu Wu, Qingyi Shi, et al.
Infection and Drug Resistance|June 14, 2019
Simulating moxalactam dosage for extended-spectrum β-lactamase-producing <i>Enterobacteriaceae</i> using blood antimicrobial surveillance network dataChen Huang, Qingyi Shi, Beiwen Zheng, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 19, 2022
Cefepime, not Piperacillin/Tazobactam use, for empirical treatment of bloodstream infections caused by Enterobacter spp.: Results from a population pharmacokinetic/pharmacodynamic analysisQingyi Shi, Chen Huang, Weizhuang Chen, et al.
Infection and Drug Resistance|May 8, 2018
In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant <i>Klebsiella pneumoniae</i>Wei Yu, Qixia Luo, Qingyi Shi, et al.
Clinical and Experimental Rheumatology|April 23, 2026
BLyS/APRIL dual inhibition for systemic sclerosis: a single-centre, single-arm, open-label clinical trial of telitaciceptQingyi Shi, Jin Zhang, Qiuxia Yu, et al.
Pageof 2